SESSION CANCELLED

Pharmacy Grand Rounds

Sickle Me Pink: Promising Advances in Sickle Cell Disease Management

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Sickle cell disease is a genetic condition that is associated with both acute and chronic complications. The mainstay of therapy for patients with sickle cell disease has been hydroxyurea. In recent years, new medications have been approved for use in sickle cell disease management. These therapies may be beneficial in helping reduce hospitalizations and acute complications such as vaso-occlusive crisis. This presentation will review the current treatment guidelines for sickle cell disease and describe the potential role of newer disease-modifying agents.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Describe the pathophysiology and complications associated with sickle cell disease
2. Review standard treatment modalities of sickle cell disease
3. Discuss recent literature regarding advancements in sickle cell disease therapy

Session Announcement

FACULTY INFORMATION

Deann N. Tims, PharmD
PGY1 Pediatric Pharmacy Resident
Mayo Eugenio Litta Children's Hospital - Rochester, MN

Deann received a Doctor of Pharmacy degree from the University of Minnesota College of Pharmacy in Duluth, MN. She is a current PGY1 Pediatric Pharmacy Resident at Mayo Eugenio Litta Children’s Hospital with practice interests in general pediatrics, hematology/oncology, and pharmacogenomics.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Deann N. Tims, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Crizanlizumab
    • L-Glutamine
    • Voxelotor

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS